Table 1 Medicines to be included in the WHO EML for JIA (those selected as most important are underlined)
From: Revising the WHO Essential Medicines List for paediatric rheumatology update
Medication | N (%) | Medication | N (%) |
|---|---|---|---|
Methotrexate | 173 (100%) | TNF Inhibitor | 168 (97%) |
−Methotrexate | −143 (83%) | −Adalimumab | −152 (88%) |
−Methotrexate | −147 (85%) | −Etanercept | −115 (66%) |
(Subcutaneous) |  | −Infliximab | −77 (45%) |
Sulphasalazine | 55 (32%) | IL6 Inhibitor | 151 (87%) |
|  |  | −Tocilizumab (Intravenous) | −121 (70%) |
|  |  | −Tocilizumab (Subcutaneous) | −90 (52%) |
Hydroxychloroquine | 77 (45%) | IL1 Inhibitor | 123 (71%) |
|  |  | −Anakinra | −120 (69%) |
|  |  | −Rilonacept | −4 (2%) |
|  |  | −Canakinumab | −31 (18%) |
Intra-articular Steroids | 157 (91%) | Abatacept | 39 (23%) |
−Triamcinolone Hexacetonide | −134 (77%) |  |  |
−Triamcinolone Acetonide | −35 (30%) |  |  |
Methylprednisolone Acetate | −32 (19%) |  |  |
Prednisolone | 150 (87%) | Rituximab | 75 (43%) |
Methylprednisolone (Intravenous) | 123 (71%) | Tofacitinib | 54 (31%) |
Azathioprine | 45 (26%) | Baricitinib | 19 (11%) |
Ciclosporin | 33 (19%) | Leflunomide | 2 (1%) |
Total N 173 | |||